Clinical Trials
51 trialsNCT05870579 2026-05-27
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Novartis
Phase 1 Recruiting
NCT07287098 2026-05-22
preEMBER
Eli Lilly and Company
Phase 2 Not yet recruiting
NCT07310420 2026-05-18
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
TerSera Therapeutics LLC
Phase 1 Recruiting
NCT05085002 2026-05-14
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT05827081 2026-05-14
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT05161195 2026-04-02
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
Phase 4 Active not recruiting
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT05607004 2025-10-30
EVANGELINE
Atossa Therapeutics, Inc.
Phase 2 Recruiting
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT04478266 2025-09-11
AMEERA-5
Sanofi
Phase 3 Terminated
NCT01673984 2025-05-23
GREAT
Ipsen
Phase 4 Terminated
NCT03936218 2025-04-17
Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer
Eurofarma Laboratorios S.A.
Phase 3 Completed
NCT03936933 2025-02-17
Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer
Eurofarma Laboratorios S.A.
Phase 3 Terminated
NCT01964170 2024-10-31
A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
Astellas Pharma Inc
Phase 3 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT02278120 2024-03-12
MONALEESA-7
Novartis
Phase 3 Completed
NCT01394263 2024-01-02
Study of Histrelin Subdermal Implant in Patients With Prostate Cancer
Endo Pharmaceuticals
Phase 3 Completed
NCT02941926 2023-10-24
COMPLEEMENT-1
Novartis
Phase 3 Completed
NCT02333370 2023-06-08
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT05110170 2023-05-16
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
Phase 3 Completed
NCT05140512 2023-05-16
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
Phase 1 Completed
NCT05856630 2023-05-12
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
Luye Pharma Group Ltd.
Phase 1 Unknown
NCT03971110 2022-12-16
A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
AstraZeneca
Phase 4 Terminated
NCT03096847 2021-10-11
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT01252693 2021-10-05
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT04563936 2021-08-26
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
Phase 3 Completed
NCT03658213 2021-05-10
LARES
AstraZeneca
Phase 3 Withdrawn
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT03450109 2019-01-07
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
Luye Pharma Group Ltd.
Phase 1 Completed
NCT01073865 2018-12-12
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
AstraZeneca
Phase 3 Completed
NCT01496131 2018-03-09
Tecemotide (L-BLP25) in Prostate Cancer
EMD Serono
Phase 2 Completed
NCT02107391 2017-05-24
Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
Sotio Biotech Inc.
Phase 2 Completed
NCT02749825 2016-04-25
Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
Pharmatech
Phase 4 Terminated
NCT01744366 2015-06-23
PANDA
Ferring Pharmaceuticals
Phase 3 Completed
NCT01242748 2015-06-03
A Degarelix Trial in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Terminated
NCT00946920 2014-06-02
A Trial of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT01088529 2014-05-15
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Cougar Biotechnology, Inc.
Phase 2 Completed
NCT00884273 2013-11-13
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Ferring Pharmaceuticals
Phase 3 Completed
NCT00831233 2013-11-11
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Terminated
NCT00833248 2012-10-04
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT00605267 2012-09-06
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
AstraZeneca
Phase 3 Completed
NCT00322348 2011-01-24
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
AstraZeneca
Phase 2 Completed
NCT00235937 2011-01-21
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
AstraZeneca
Phase 2 Completed
NCT00888082 2010-12-10
PROOF
AstraZeneca
Phase 3 Withdrawn
NCT00303524 2009-12-23
Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients
AstraZeneca
Phase 2 Completed
NCT00841113 2009-02-11
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
Speciality European Pharma Limited
Phase 3 Completed